Navigation Links
Anadys Pharmaceuticals Augments Management Team and Board of Directors
Date:1/6/2011

in the biotechnology and pharmaceutical industries as an investment banker, Board member and company founder and investor.  Dr. Papadopoulos is a Board member of several companies, including Biogen Idec and Exelixis, Inc., where he is Chairman.  

Dr. Papadopoulos added, "On behalf of all of us at Anadys I would like to thank Steve Holtzman for his years of service as a member as well as for serving as Chairman of our Board.  We will miss his unique insights and wise counsel, but we wish him well in his new endeavor at Biogen Idec."

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C.  The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines.  Anadys has initiated a Phase IIb study of ANA598, the Company's DAA, added to current standard of care for the treatment of hepatitis C.  The Company is also preparing to resume clinical development of ANA773, the Company's oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements."  Such statements include, but are not limited to, references to Anadys' ability to execute its corporate objectives in the coming year.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.  For example, the results of preclinical and early clinical studies may not be predictive of future results, and Ana
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference
2. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2009 Financial Results
3. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
4. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
5. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
6. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
7. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
8. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
9. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
10. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
11. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... NEW YORK , Oct. 24, ... formerly Access Pharmaceuticals, Inc. (ACCP), a biopharmaceutical company ... has implemented a 1-for-50 reverse split of its ... on Friday, October 24, 2014. PlasmaTech,s common stock ... CUSIP number 72754H109 and temporary ticker symbol "ACCPD". ...
(Date:10/22/2014)... , Oct. 22, 2014 New test innovations ... in vitro diagnostic (IVD) test industry, especially as companies ... market researcher listed more than 25 testing innovations in ... the future of IVD products. Kalorama details the new approaches ... Worldwide Market for In Vitro Diagnostic Tests , ...
(Date:10/22/2014)... Md. (PRWEB) October 21, 2014 Shimadzu ... an LC/MS/MS data tool for the pain management and ... of data processing and review by allowing users to ... to clinicians. , QuantAnalytics allows analysts to filter ... This expedites data processing by eliminating the need to ...
(Date:10/22/2014)... Rock Hill, SC (PRWEB) October 22, 2014 ... the expansion of its cardiovascular pharmacogenetics menu, which ... improved patient outcomes. With PCLS’s evidence-based results, ... individual needs and optimize their therapy, while minimizing ... , In the U.S., according to the FDA ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website 2Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3
... Cause of ... Death, Yearly, Liver Cancer Alone ... Growing; Viral Hepatitis Declines, MILAN, April 23 More than 6,000 physicians ... the opening sessions of the 43rd Annual Meeting of the,European Association for the ...
... image are better than one for analyzing tumors , ... determine the amount of oxygen in a tumor very useful, because ... a poor outcome. A new method to do this and to ... been developed and used to image tumors in mice by Murali ...
... Some of the biggest-selling,biologics developed during the boom years ... and insulin, have lost patent,protection in the U.S. in ... $40 billion. This opens up a huge potential market ... a new report by Kalorama,Information, Biogenerics: the World Market ...
Cached Biology Technology:Liver Diseases: A Huge European Health Burden, But Some Trends are Positive 2Liver Diseases: A Huge European Health Burden, But Some Trends are Positive 3JCI table of contents: April 22, 2008 2JCI table of contents: April 22, 2008 3JCI table of contents: April 22, 2008 4JCI table of contents: April 22, 2008 5JCI table of contents: April 22, 2008 6JCI table of contents: April 22, 2008 7JCI table of contents: April 22, 2008 8JCI table of contents: April 22, 2008 9JCI table of contents: April 22, 2008 10JCI table of contents: April 22, 2008 11JCI table of contents: April 22, 2008 12Huge Potential in Biosimilars if Generic Providers Overcome Regulatory Hurdles 2
(Date:10/14/2014)... in Cancer Research shows SIRT6—a protein known ... promote the development of skin cancers by turning on ... sun-damaged skin cells. , Previously considered protective, SIRT6 is ... that help regulate genomic stability and prevent some of ... DNA damage, which can lead to cancer. This study, ...
(Date:10/14/2014)... N.Y. – Scientists have sequenced the house fly genome ... one might expect from an insect that thrives in ... published Oct. 14 in the journal Genome Biology ... biology and of how flies quickly adapt to resist ... Adult house flies (Musca domestica) carry and transmit more ...
(Date:10/14/2014)... new kind of stem cell that can become either a ... according to a study published today in the journal ... type contradicts current theory on how organs arise from cell ... of, and future treatment for, liver cancer., Thanks to stem ... being made up of more than 200 cell types. The ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2House fly genome reveals expanded immune system 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3
... provide a look at the ash and gas clouds being ... NOAA,s GOES-13 satellite to provide a week long look at ... westerly winds carry the debris (ash and smoke) far to ... down the ash before it can go far in the ...
... 2012 Scientists at The Scripps Research Institute have ... the market to treat neuropathic pain and epilepsy, helps ... treatments, gabapentin targets stress systems in the brain that ... 12-week trial of 50 treatment-seeking cannabis users, those who ...
... /PRNewswire-iReach/  -- Global Information Inc. is announces limited time ... important Boston healthcare conferences: Next-Gen Kinase ... rapidly maturing kinase inhibitors field will gather to explore ... Next-Gen Kinase Inhibitors Conference in Cambridge, MA. ...
Cached Biology News:NASA's new satellite movie of 1 week's ash activity from Mexico's Popocatepetl Volcano 2Scripps research scientists find anticonvulsant drug helps marijuana smokers kick the habit 2Scripps research scientists find anticonvulsant drug helps marijuana smokers kick the habit 3Attendees Save Up To $800 on Boston-area Pharmaceutical and Healthcare Conferences, Early Bird Discounts Expiring April 27 2Attendees Save Up To $800 on Boston-area Pharmaceutical and Healthcare Conferences, Early Bird Discounts Expiring April 27 3
Economical and manually filled LN2 vacuum insulated storage container offers high capacity and low nitrogen consumption while offering convenient storage of samples....
... DNase I Amplification Grade ... DNA to oligodeoxyribonucleotides. The ... units/mg. DNAse I Amplification ... and tested for absence ...
... of Cell Cultures (ECACC) in conjunction with ... West of England, Bristol, UK, have produced ... of HER2, oestrogen and progresterone receptor assays. ... of formalin fixed, breast cancer cell lines; ...
... 3C protease from human rhinovirus (HRV 3C) ... brand line of restriction grade proteases. The ... 6XHis-fusion protein, which recognizes the same cleavage ... small, 22 KDa size of the protease, ...
Biology Products: